Switch to
More onapp

How to use scorecard? Learn more

Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹34,659 cr, stock is ranked 217
High RiskStock is 3.13x as volatile as Nifty
290.000.40 (+0.14%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
MidcapWith a market cap of ₹34,659 cr, stock is ranked 217
High RiskStock is 3.13x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
28.88
PB RatioPB Ratio
1.54
Dividend YieldDiv. Yield
0.52%
Sector PESector PE
51.72
Sector PBSector PB
5.89
Sector Div YldSctr Div Yld
0.55%

Forecast & RatingsDetailed Forecast 

53%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

Brands

Biocon

Biotech company

Investor PresentationView older 

Aug 11, 2023

PDF
View Older Presentations

Brands

Biocon

Biotech company

Financial TrendFinancial statements 

20202021202220236.537.418.4011.550.750.740.650.46
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Shareholders meeting 
Announced OnApr 23, 2024

Biocon Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. | Download

Biocon Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. | Download

Press Release 
Announced OnApr 17, 2024

Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled "Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.". | Download

Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled "Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.". | Download

Cash Dividend 
Ex. DateJul 7, 2023

Final • Div/Share: ₹ 1.5

See all events